AIM ImmunoTech (STU:HXB) EPS (Basic): €-6.28 (TTM As of Mar. 2026)


STU:HXB AIM ImmunoTech Inc STU:HXB
33 GF Score
Price €5.76
GF Value €41.59
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech EPS (Basic)?

AIM ImmunoTech STU:HXB 33 EPS (Basic) is €-6.28 as of Mar. 2026. GuruFocus rates STU:HXB with a GF Score™ of 33/100 and a GF Value™ of €41.59. The stock has 6 warning signs investors should review.

AIM ImmunoTech's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.60. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-6.28.

AIM ImmunoTech's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.60. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-6.28.

AIM ImmunoTech's EPS without NRI for the three months ended in Mar. 2026 was €-0.50. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -6.19.

During the past 3 years, the average EPS without NRI Growth Rate was 38.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 20.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 45.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, AIM ImmunoTech's highest 3-Year average EPS without NRI Growth Rate was 70.20% per year. The lowest was -21.10% per year. And the median was 11.60% per year.

AIM ImmunoTech  (STU:HXB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

AIM ImmunoTech EPS (Basic) Related Terms

AIM ImmunoTech EPS (Basic) Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech EPS (Basic) Chart

AIM ImmunoTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -35.37 -37.72 -54.97 -29.53 -7.36

AIM ImmunoTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.63 -3.19 -1.34 -1.16 -0.60
STU:HXB
33GF Score
AIM ImmunoTech Inc STU:HXB
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

AIM ImmunoTech's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-11.92-0)/1.619
=-7.36

AIM ImmunoTech's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.615-0)/4.351
=-0.60

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-6.28 mean?
AIM ImmunoTech (STU:HXB) has a EPS (Basic) of €-6.28 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on AIM ImmunoTech and its competitors.
Is AIM ImmunoTech's EPS (Basic) too high?
AIM ImmunoTech's current EPS (Basic) is €-6.28. Overall, AIM ImmunoTech has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's EPS (Basic) compare to BGMS and FBLG?
AIM ImmunoTech's EPS (Basic) of €-6.28 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current EPS (Basic) is €-6.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
AIM ImmunoTech (STU:HXB) has a current EPS (Basic) of €-6.28. The stock's GF Value™ is €41.59, compared to a current price of €5.76 — trading 86.1% below its estimated fair value. The current EPS (Basic) is €-6.28. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For AIM ImmunoTech (STU:HXB), the current EPS (Basic) is €-6.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (STU:HXB) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of €5.76 is trading 86.1% below its estimated GF Value™ of €41.59.

Key valuation signals for STU:HXB:

  • EPS (Basic): €-6.28
  • GF Value™: €41.59 vs. price of €5.76 (86.1% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the STU:HXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM ImmunoTech Business Description

Other Exchanges AIM:USA0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for STU:HXB

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.76
Price
€41.59
GF Value